



Attorney's Docket No.: 07039-501US1 / MMV-03-089

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Peter J. Wettstein *et al.* Art Unit : 1644
Serial No. : 10/587,925 Examiner : Unknown
Filed : August 2, 2006
Title : COMPLEXED POLYPEPTIDE AND ADJUVANT FOR IMPROVED
VACCINES

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form.

Copies of communications from a foreign patent office in a counterpart application are also enclosed.

This statement is being filed within three months of the filing date of the application. No fees are believed to be due. If this is incorrect, please apply any necessary charges, or any credits, to Deposit Account No. 06-1050, referencing Attorney Docket No. 07039-501US1.

Respectfully submitted,

Date: October 3, 2006

Allyson R. Hatton, Ph.D.
Reg. No. 54,154

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
21406975.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL


I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Typed or Printed Name of Person Signing Certificate

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-501US1	Application No. 10/587,925
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Peter J. Wettstein <i>et al.</i>	
		Filing Date August 2, 2006	Group Art Unit 1644



Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AA	WO 02/32451	04/25/2002	WIPO				
	AB	WO 03/082327	10/09/2003	WIPO				
	AC	WO 05/076975	08/25/2005	WIPO				
	AD							
	AE							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AF	Buschle <i>et al.</i> , "Transloading of tumor antigen-derived peptides into antigen-presenting cells," <i>Proc. Natl. Acad. Sci. USA</i> , 94:3256-3261, 1997.
	AG	Davis <i>et al.</i> , "CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B surface Antigen" <i>J. Immunol.</i> 160:870-876, 1998.
	AH	Dyer <i>et al.</i> , "The quiet revolution: A new synthesis of biological knowledge.,," <i>Journal of Biological Education</i> 5:15-24, 1971.
	AI	Engelhard <i>et al.</i> , "Influenza A-Specific, HLA-A2.1 – Restricted Cytotoxic T Lymphocytes from HLA-A2.1 Transgenic Mice Recognize Fragments of the M1 Protein" <i>J. Immunol.</i> , 146:1226-1232, Feb. 1991.
	AJ	Greenfield <i>et al.</i> , "An H-YD ^b epitope is enclosed by a novel mouse Y chromosome gene" <i>Nature Genetics</i> 14:474-478, 1996.
	AK	Heit <i>et al.</i> , "Cutting Edge: Toll-Like Receptor 9 Expression is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells," <i>J. Immunol.</i> 170:2802-2805, 2003.
	AL	King and Jukes, "Non-Darwinian Evolution," <i>Science</i> , 164:788-798, 1969.
	AM	King <i>et al.</i> , "Deletion Mapping by Immunoselection against the H-Y Histocompatibility Antigen Further Resolves the Sxr ^a Region of the Mouse Y Chromosome and Reveals Complexity of the Hya Locus," <i>Genomics</i> 24:159-168, 1994.
	AN	Krieg, "CPG Motifs in Bacterial DNA and Their Immune Effects," <i>Annu. Rev. Immunol.</i> , 20:709-760, 2002.
	AO	Le <i>et al.</i> , "Cytotoxic T Cell Responses in HLA-A2.1 Transgenic Mice Recognition of HLA Alloantigens and Utilization of HLA-A2.1 as a Restriction Element," <i>J. Immunol.</i> , 142:1366-1371 1989.
	AP	Lingnau <i>et al.</i> , "Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (GpG-ODN) for enhanced and prolonged immune responses and prevent the CpG-ODN-induced systemic release of pro-inflammatory cytokines," <i>Vaccine</i> 20:3498-3508, 2002.
	AQ	Lu <i>et al.</i> , "TAP-Independent Presentation of CTL Epitopes by Trojan Antigens," <i>J. Immunol.</i> 166:7063-7071, 2001.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-501US1	Application No. 10/587,925
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Peter J. Wettstein <i>et al.</i>	
		Filing Date August 2, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AR	Lührs <i>et al.</i> "Induction of Specific Immune Responses by Polycation-Based Vaccines," <i>J. Immunol.</i> 169:5217-5226, 2002.
OCT 06 2006 PATENT & TRADEMARK OFFICE	AS	Malarakkannan <i>et al.</i> , "The Molecular and Functional Characterization of a Dominant Minor H Antigen, H60," <i>J. Immunol.</i> , 161:3501-3509, 1998.
	AT	Mattner <i>et al.</i> , "Vaccination with Poly-L-Arginine As Immunostimulant for Peptide Vaccines: Induction of Potent and Long-Lasting T-Cell Responses against Cancer Antigens," <i>Cancer Res.</i> , 62:1477-1480, 2002
	AU	Maurer <i>et al.</i> , "CpG-DNA Aided Cross-Presentation of Soluble Antigens by Dendritic Cells," <i>J. Immunol.</i> 32:2356-2364, 2002
	AV	Schirmbeck <i>et al.</i> , "Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4 ⁺ T Cell Help-Independent, Priming of CD8 ⁺ T Cells," <i>J. Immunol.</i> 171:5198-5207, 2003.
	AW	Schmidt <i>et al.</i> , "Cell-free Tumor Antigen Peptide-Based Cancer Vaccines," <i>Proc. Natl. Acad. Sci. USA</i> , 94:3262-3267, 1997.
	AX	Vivès <i>et al.</i> , "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus," <i>J. of Biological Chem.</i> , 272:16010-16017, 1997.
	AY	Zwaveling <i>et al.</i> , "Established Human Papillomavirus Type 16-Expressing Tumors are Effectively Eradicated following Vaccination with Long Peptides," <i>J. of Immunol.</i> , 169:350-358, 2002.

Examiner Signature <i>/Marianne DiBrino/</i>	Date Considered 12/22/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	